Vitamin D3.

Vitamin D3's main job is switching on the intestinal transport proteins that carry calcium across the gut wall, so calcium taken alongside it is absorbed more efficiently than calcium on its own. This is the mechanism behind the long-standing practice of formulating the two together for bone support.

Vitamin D3 increases how much calcium the gut takes in, while vitamin K2 activates the proteins osteocalcin and matrix Gla protein that bind that calcium into bone and keep it from settling in soft tissue. Paired, the calcium D3 pulls in has the machinery to be put where it belongs.

The liver and kidney enzymes that convert vitamin D3 into its active hormone form are magnesium-dependent, so magnesium is a required cofactor for putting D3 to work. When magnesium is low, supplemental D3 tends to stay in its inactive, stored form.

Vitamin D3 raises calcium absorption and drives production of osteocalcin and matrix Gla protein, and both of those proteins only bind calcium once vitamin K has carboxylated them. MK-7 is the long-lived menaquinone that reaches bone and vessel wall tissue, so it carries the carboxylation step that D3 creates demand for.

Vitamin D3 upregulates the Gla proteins that direct calcium into bone matrix, and those proteins stay inactive until a vitamin K-dependent carboxylase adds their glutamate carboxyl groups. Raising D3 without vitamin K raises the amount of protein waiting on that step.

The 25-hydroxylase in liver and the 1-alpha-hydroxylase in kidney are magnesium-dependent enzymes. A well-absorbed magnesium form supplies the cofactor that converts cholecalciferol into its circulating and active metabolites.

The vitamin D receptor reads DNA through two zinc-finger motifs, so zinc availability sits inside the step where 1,25-dihydroxyvitamin D changes gene transcription. Zinc status therefore shapes how much of a given D3 intake is expressed as a signal.

The vitamin D receptor works as a heterodimer with the retinoid X receptor, so retinoid status shapes vitamin D transcription directly. At high retinol intakes the two compete for that shared partner and for the same lipid absorption pathway, so the interaction runs both helpful and competitive depending on dose.

Cholecalciferol needs bile salt micelles and dietary fat to cross the enterocyte, so taking it alongside a long-chain fatty acid source raises the fraction absorbed compared with a fasted dose. This is standard softgel formulation practice as well as physiology.

Medium-chain triglycerides emulsify quickly and give a fat-soluble vitamin a carrier phase for micelle formation in the small intestine. Formulators use them as the oil base in D3 drops and softgels for that reason.

Phylloquinone is the form that keeps the liver's vitamin K cycle running, which is the carboxylase system shared with the bone and vessel Gla proteins vitamin D3 induces. It covers the hepatic end of the same carboxylation requirement MK-7 covers in peripheral tissue.

Bile salts emulsify dietary fat and package fat-soluble vitamins into mixed micelles, the step that precedes uptake across the brush border. Where bile flow is reduced, absorption of all fat-soluble vitamins falls together. This is settled digestive physiology rather than a combination finding.

Lipase releases free fatty acids and monoglycerides, and those products are what build the micelles vitamin D3 travels in. Without lipolysis, the vitamin stays in an oil phase the intestine cannot take up efficiently. Textbook lipid digestion, no trial required.

Phosphatidylcholine contributes to the micelle surface that solubilises cholecalciferol in the gut lumen. In formulation, it is the emulsifier that keeps a fat-soluble vitamin dispersed in a water-based or powder format. The mechanism is delivery physics, not an added biological action.

Cholecalciferol is an oil-phase molecule, so liquid drops, gummies and dry beadlets rely on an emulsifier to keep it evenly distributed. Lecithin supplies that function and also contributes phospholipid to micelle formation. This is manufacturing practice with a mechanistic basis behind it.

Vitamin D3 and alpha-tocopherol both depend on micellar solubilisation and on transporters including SR-B1 and NPC1L1. High-dose co-administration sets up competition for that limited capacity. The competition is described for fat-soluble vitamins as a class; the size of it at ordinary supplement doses is not well quantified.

Boron intake has been linked to changes in calcium and magnesium retention and in vitamin D metabolite levels in small balance studies. The mechanism is not mapped to a specific enzyme, so this stays a marker-level observation. It is a reason to note the pairing, not to claim an outcome.

Charcoal's large nonpolar surface binds fat-soluble molecules before they can be absorbed, which includes cholecalciferol taken at the same time. The interaction is a physical adsorption and applies to any co-ingested lipophile. Spacing the two apart is the practical response.

Strontium is a calcium mimic and uses shared intestinal transport, so raising vitamin D activity increases absorption of both cations rather than calcium alone. Co-dosing therefore changes the ratio arriving at bone. The competition is established for the ions; its consequences for a supplement schedule are less well mapped.

Collagen supplies the organic matrix while vitamin D-dependent calcium absorption supplies what mineralises it, so the two act on different halves of the same tissue. That division of labour is anatomically settled. Whether combining them changes a measured bone endpoint is a separate question this row does not answer.

Hyperforin activates the pregnane X receptor, raising CYP3A4 expression; CYP3A4 is one of the enzymes that inactivates 25-hydroxyvitamin D and its active form. Faster catabolism means a given intake yields lower circulating metabolite levels. The induction step is established; the quantitative effect on vitamin D status is not well characterised.

CYP2R1 in liver and CYP27B1 in kidney need reducing equivalents supplied through FAD-dependent reductase partners, and riboflavin is the precursor of FAD. That places riboflavin upstream of both activation steps as a cofactor supply issue. It is a biochemical dependency, not a dose-response claim.